Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Cystic fibrosis stories

Aug 10, 2026

Sionna Therapeutics halts cystic fibrosis drug development after trial failure

Sionna Therapeutics discontinued development of its experimental cystic fibrosis pill after it failed to show meaningful benefit when added to standard treatment in a mid-stage trial, causing shares to plunge.

Aug 10, 2026·2 sources
00

Top claims

  • ▪Sionna Therapeutics' stock fell between 90% and 92% in pre-market trading on August 10, 2026, following the SION-719 trial failure announcement.
  • ▪Sionna Therapeutics stated that variations in patient test results and differences in Trikafta levels may have influenced the SION-719 trial outcome.
  • ▪SION-719 failed to significantly lower sweat chloride levels in patients, which is a key measure of cystic fibrosis treatment efficacy.

Topics

Drug developmentPharmaceutical IndustryClinical trials

Featured Stories

OpenAI pauses development of Astra AI model over critical cybersecurity capability concerns

OpenAI pauses development of Astra AI model over critical cybersecurity capability concerns

Aug 7, 2026·2 sources